key: cord-1015003-0lj7tbix authors: Chemaitelly, H.; Ayoub, H.; AlMukdad, S.; Coyle, P.; Tang, P.; YASSINE, H. M.; Al-Khatib, H. A.; Smatti, M. K.; Hasan, M. R.; Al-Kanaani, Z.; Al-Kuwari, E.; Jeremijenko, A.; Kaleeckal, A. H.; Latif, A. N.; Shaik, R. M.; Abdul-Rahim, H. F.; Nasrallah, G.; Al-Kuwari, M. G.; Butt, A. A.; Al-Romaihi, H. E.; Al-Thani, M. H.; Al-Khal, A.; Bertollini, R.; Abu-Raddad, L. J. title: Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar date: 2022-03-13 journal: nan DOI: 10.1101/2022.03.13.22272308 sha: ba3ea70c8fff5bed0b0863da82907bce21260423 doc_id: 1015003 cord_uid: 0lj7tbix The SARS-CoV-2 Omicron (B.1.1.529) variant has two subvariants, BA.1 and BA.2, that are genetically quite divergent. We conducted a matched, test-negative, case-control study to estimate duration of protection of mRNA COVID-19 vaccines, after the second dose and after a third/booster dose, against BA.1 and BA.2 infections in Qatar population. BNT162b2 effectiveness against symptomatic BA.1 infection was highest at 46.6% (95% CI: 33.4-57.2%) in the first three months after the second dose, but then declined to ~10% or below thereafter. Effectiveness rapidly rebounded to 59.9% (95% CI: 51.2-67.0%) in the first month after the booster dose, but then started to decline again. BNT162b2 effectiveness against symptomatic BA.2 infection was highest at 51.7% (95% CI: 43.2-58.9%) in the first three months after the second dose, but then declined to ~10% or below thereafter. Effectiveness rapidly rebounded to 43.7% (95% CI: 36.5-50.0%) in the first month after the booster dose, but then declined again. Effectiveness against COVID-19 hospitalization and death was in the range of 70-80% any time after the second dose, and was greater than 90% after the booster dose. Similar patterns of protection were observed for the mRNA-1273 vaccine. mRNA vaccines provide only moderate and short-lived protection against symptomatic Omicron infections, with no discernable differences in protection against either the BA.1 or BA.2 subvariants. Vaccine protection against COVID-19 hospitalization and death is strong and durable after the second dose, but is more robust after a booster dose. Qatar endured a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron (B.1.1.529) 1 wave that started on December 19, 2021 and peaked in mid-January, 2022 [2] [3] [4] [5] . The wave was first dominated by the BA.1 Omicron subvariant, but within a few days, the BA.2 subvariant predominated ( Figure 1 ). While BA.1 and BA.2 remain classified as subvariants of the Omicron variant, there is considerable genetic distance between them 6 . Accordingly, we investigated duration of protection of BNT162b2 (Pfizer-BioNTech) 7 any severe (acute-care hospitalization) 9 , critical (intensive-care-unit hospitalization) 9 , or fatal 10 infection due to either Omicron subvariant. Vaccine effectiveness was estimated using the test-negative, case-control study design 11,12 , 50 .0%) in the first month after the booster dose, but then declined to 40.2% (95% CI: 34. .7%) in the second month and thereafter. A similar pattern was observed for mRNA-1273 effectiveness ( Figure 3D and Table 4 ). BNT162b2 effectiveness against any symptomatic Omicron infection, regardless of subvariant, was highest at 47.8% (95% CI: 40.8-53.9%) in the first three months after the second dose, but then declined to ~15% or below thereafter ( Figure 4A and Table 3 ). Effectiveness rapidly rebounded to 49.5% (95% CI: 44.3-54.1%) in the first month after the booster dose, but then declined to 39.4% (95% CI: 34.4-44.0%) in the second month and thereafter. A similar pattern was observed for mRNA-1273 effectiveness ( Figure 4B and Table 4 ). Effectiveness against any severe, critical, or fatal COVID-19 due to an Omicron infection, regardless of subvariant, was in the range of 70-80% at any time after the second dose for both the BNT162b2 and mRNA-1273 vaccines (Figures 4C and 4D and Table 5 ). However, BNT162b2 effectiveness against any severe, critical, or fatal COVID-19 after the booster dose was greater than 90%. 95% CIs around estimates of mRNA-1273 effectiveness against any severe, critical, or fatal COVID-19 after the booster dose lacked adequate statistical precisionthere were too few hospitalized COVID-19 cases among mRNA-1273 vaccinated persons (Table 5 ). Sensitivity analyses adjusting for documented prior infection and healthcare worker status yielded similar findings to the main analyses (Supplementary Tables 1 and 2) . Sensitivity analyses to assess the impact of excluding children <12 years of age (Supplementary Tables 3 and 4 ), or individuals <20 years of age (Supplementary Tables 5 and 6 ), also yielded similar findings to the main analyses. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101/2022.03.13.22272308 doi: medRxiv preprint No discernable differences were observed in the duration of mRNA vaccine protection against BA.1 versus BA.2 symptomatic infection. For each of these subvariants, vaccine effectiveness against symptomatic infection was ~50% in the first three months after the second dose, but declined to negligible levels thereafter. Effectiveness rapidly rebounded after the booster dose to reach similar levels to those seen right after the second dose, but appeared to wane again starting from the second month after the booster dose. There were also no discernable differences in effectiveness of BNT162b2 vaccine versus mRNA-1273 vaccine. Despite only moderate and rapidly waning protection against symptomatic infection, mRNA vaccine effectiveness against COVID-19 hospitalization and death due to Omicron infections was strong at greater than 70% after the second dose. It was also higher after the booster dose at greater than 90%. These findings support the durability of vaccine protection against COVID-19 hospitalization and death for at least several months after receiving the second dose, 13, 14 but also demonstrate the importance of booster vaccination in achieving robust protection against any hospitalization and death due to Omicron infections. These findings suggest the need to consider rapid implementation of booster vaccination campaigns coincident with the emergence of a new wave or variant, at least to those most vulnerable to COVID-19 hospitalization and death. This study has limitations. With the lower severity of Omicron infections 20 and the young population of Qatar 15, 21 , case numbers were insufficient to estimate the duration of protection against COVID-19 hospitalization and death for each subvariant separately. BA.1 and BA.2 ascertainment was based on proxy criteria, presence or absence of an S-gene "target failure" using the TaqPath PCR assay (Methods), but this method of ascertainment is well established not only for Omicron subvariants, but also for other variants such as Alpha 22-24 . Some Omicron All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101/2022.03.13.22272308 doi: medRxiv preprint infections may have been misclassified Delta infections, but this is not likely, as Delta incidence was limited during the study duration (Methods). Vaccine protection was assessed for only several months after the second dose, and only several weeks after the booster dose. Longer-term protection against symptomatic infection and COVID-19 hospitalization and death remain uncertain. Vaccine effectiveness reached small but statistically significant negative values at 7 months or more after the second dose. Negative estimated effectiveness likely reflects an effect of bias and not true negative biological effectiveness. This bias may have risen from vaccinated persons having a higher social contact rate or adhering less to safety measures than unvaccinated persons [25] [26] [27] . With the high vaccine coverage among adults in Qatar (>85%) 13 , this bias may have also risen because the reference group of unvaccinated individuals included mainly children or young persons; therefore, it may not be representative of the wider population. However, sensitivity analyses excluding children and young persons confirmed the same study findings (Supplementary Tables 3-6) . Unvaccinated adults are a small minority that may not be truly immune-naïve due to undocumented prior SARS-CoV-2 infections, especially now that we are two years into this pandemic. Bias due to depletion of the susceptible population may lead to underestimation of vaccine effectiveness 28 , even in the test-negative, case-control, study design, which is less prone to effect of this bias 13 . While matching was done for sex, age, and nationality, this was not possible for other factors, such as comorbidities, as such data are not available. However, matching by these factors provided demonstrable control of bias in studies of different epidemiologic designs and that used control groups in Qatar 13, 14, [29] [30] [31] . Effectiveness was assessed using an observational, test-negative, case-control, study design 11, 12 , rather than a design in which cohorts of vaccinated and unvaccinated individuals were followed up. However, the cohort study design applied earlier to the same population of Qatar yielded findings similar to those of the test-negative case-control design 30,32,33 , supporting the validity of this standard approach in assessing vaccine effectiveness 11, 12, 30, 34 . Moreover, our recent study of the effectiveness of booster vaccination against any symptomatic Omicron infection, relative to that of the primary series, used a cohort study design 5 and its results are consistent with results generated in the present study using the test-negative, case-control study design. Nonetheless, one cannot exclude the possibility that in real-world data, bias could arise in unexpected ways, or from unknown sources, such as subtle differences in test-seeking behavior or changes in the pattern of testing with introduction of other testing modalities, such as rapid antigen testing (RAT). For example, with the large Omicron wave in Qatar, use of RAT was expanded to supplement PCR testing starting from January 5, 2022. However, RAT was broadly implemented in the population and probably did not differentially affect PCR testing to introduce bias. With the small proportion of Qatar's population ≥50 years of age 15 13 , the likelihood of bias is perhaps minimized. Extensive sensitivity and additional analyses were conducted to investigate effects of potential bias in our earlier studies for the BNT162b2 13 and mRNA-1273 14 vaccines, which used the same methodology used here. These included different adjustments in the 9 analysis, different approaches for factoring prior infection in the analysis, and different study inclusion and exclusion criteria to investigate whether effectiveness estimates could have been biased 13, 14 . These analyses showed consistent findings 13, 14 . In conclusion, mRNA vaccines provide only moderate protection against symptomatic BA.1 and BA.2 Omicron infections, with no discernable differences in protection against either the BA.1 or BA.2 subvariants. Protection also wanes rapidly to negligible levels, starting four months after the second dose. Vaccine protection rebounds after booster vaccination, but also appears to wane thereafter. Meanwhile, vaccine protection against COVID-19 hospitalization and death is strong and durable after the second dose, and is most robust after a booster dose. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. collection, data analysis, data interpretation, or writing of the article. HC co-designed the study, performed the statistical analyses, and co-wrote the first draft of the article. LJA conceived and co-designed the study, led the statistical analyses, and co-wrote the first draft of the article. PT and MRH conducted the multiplex, RT-qPCR variant screening and viral genome sequencing. HY, HAK, and MKS conducted viral genome sequencing. All authors contributed to data collection and acquisition, database development, discussion and interpretation of the results, and to the writing of the manuscript. All authors have read and approved the final manuscript. Dr. Butt has received institutional grant funding from Gilead Sciences unrelated to the work presented in this paper. Otherwise, we declare no competing interests. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101/2022.03.13.22272308 doi: medRxiv preprint Abbreviations: IQR, interquartile range; PCR, polymerase chain reaction; SMD, standardized mean difference. * Cases and controls were matched one-to-two by sex, 10-year age group, nationality, and calendar week of PCR test. † SMD is the difference in the mean of a covariate between groups divided by the pooled standard deviation. An SMD<0.1 indicates adequate matching. ‡ Cases and controls were matched one-to-one by sex, 10-year age group, nationality, and calendar week of PCR test. § Cases and controls were matched two-to-one by sex, 10-year age group, nationality, and calendar week of PCR test. ¶ SMD is for the mean difference between groups divided by the pooled standard deviation. ** Nationalities were chosen to represent the most populous groups in Qatar. Abbreviations: IQR, interquartile range; PCR, polymerase chain reaction; SMD, standardized mean difference. * Cases and controls were matched one-to-two by sex, 10-year age group, nationality, and calendar week of PCR test. † SMD is the difference in the mean of a covariate between groups divided by the pooled standard deviation. An SMD<0.1 indicates adequate matching. ‡ Cases and controls were matched one-to-one by sex, 10-year age group, nationality, and calendar week of PCR test. § Cases and controls were matched two-to-one by sex, 10-year age group, nationality, and calendar week of PCR test. ¶ SMD is for the mean difference between groups divided by the pooled standard deviation. ** Nationalities were chosen to represent the most populous groups in Qatar. Abbreviations: CI, confidence interval; PCR, polymerase chain reaction. * A symptomatic infection was defined as a PCR-positive nasopharyngeal swab conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection. † In each analysis for a specific time-since-vaccination stratum, we included only those vaccinated in this specific time-since-vaccination stratum and those unvaccinated. Only matched pairs of PCR-positive and PCR-negative persons, in which both members of the pair were either unvaccinated or fell within each timesince-vaccination stratum have been included in the corresponding vaccine effectiveness estimate. Thus, the number of cases (and controls) varied across time-sincevaccination analyses. ‡ Vaccine effectiveness was estimated using the test-negative, case-control study design 11, 12 . § Cases and controls were matched one-to-two by sex, 10-year age group, nationality, and calendar week of PCR test. ¶ Cases and controls were matched one-to-one by sex, 10-year age group, nationality, and calendar week of PCR test. ** Cases and controls were matched two-to-one by sex, 10-year age group, nationality, and calendar week of PCR test. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Abbreviations: CI, confidence interval; PCR, polymerase chain reaction. * A symptomatic infection was defined as a PCR-positive nasopharyngeal swab conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection. † In each analysis for a specific time-since-vaccination stratum, we included only those vaccinated in this specific time-since-vaccination stratum and those unvaccinated. Only matched pairs of PCR-positive and PCR-negative persons, in which both members of the pair were either unvaccinated or fell within each timesince-vaccination stratum have been included in the corresponding vaccine effectiveness estimate. Thus, the number of cases (and controls) varied across time-sincevaccination analyses. ‡ Vaccine effectiveness was estimated using the test-negative, case-control study design 11, 12 . § Cases and controls were matched one-to-two by sex, 10-year age group, nationality, and calendar week of PCR test. ¶ Cases and controls were matched one-to-one by sex, 10-year age group, nationality, and calendar week of PCR test. ** Cases and controls were matched two-to-one by sex, 10-year age group, nationality, and calendar week of PCR test. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101/2022.03.13.22272308 doi: medRxiv preprint A and B, respectively) and against any severe 9 , critical 9 , or fatal 10 COVID-19 due to an Omicron infection (panels C and D, respectively). Data are presented as effectiveness point estimates. Error bars indicate the corresponding 95% confidence intervals. Abbreviations: CI, confidence interval; PCR, polymerase chain reaction. * In each analysis for a specific time-since-vaccination stratum, we included only those vaccinated in this specific time-since-vaccination stratum and those unvaccinated. Only matched pairs of PCR-positive and PCR-negative persons, in which both members of the pair were either unvaccinated or fell within each time-since-vaccination stratum have been included in the corresponding vaccine effectiveness estimate. Thus, the number of cases (and controls) varied across time-since-vaccination analyses. † Cases and controls were matched one-to-five by sex, 10-year age group, nationality, and calendar week of PCR test. ‡ Severity 9 , criticality 9 , and fatality 10 were defined as per World Health Organization guidelines. § Vaccine effectiveness was estimated using the test-negative, case-control study design 11, 12 . ¶ Confidence interval could not be estimated using conditional logistic regression because of zero events among those vaccinated. Hamad Medical Corporation and Weill Cornell Medicine-Qatar Institutional Review Boards approved this retrospective study with waiver of informed consent. The study was reported following the Strengthening the Reporting of Observational studies in Epidemiology (STROBE) guidelines. The STROBE checklist is found in Supplementary Table 7 . This study was conducted in the resident population of Qatar, applying methodology that was Every PCR test conducted in Qatar is categorized based on symptoms and the reason for testing. Qatar has young, international demographics. Only 9% of Qatar's population is ≥50 years of age and 89% are international expatriates from over 150 countries 15, 35 . The vast majority of individuals were vaccinated in Qatar, but if vaccinated elsewhere, those vaccinations were still registered in the health system at the port of entry upon arrival in Qatar. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 11, 12, 30, 34 Matching was implemented to control for established differences in the risk of exposure to SARS-CoV-2 infection in Qatar [15] [16] [17] [18] [19] . Only the first PCR-positive test during the study was included for each case, whereas all PCRnegative tests during the study were included for each control. Controls included individuals with no record of a positive PCR or rapid-antigen test (RAT) during the study period. Only PCR tests conducted because of clinical suspicion of infection, i.e., symptoms indicative of a respiratory tract infection, were included in the analysis for cases and controls. All persons who received a vaccine other than BNT162b2 or mRNA-1273, or who received a different mix of vaccines, were excluded. These inclusion and exclusion criteria were implemented to minimize different types of potential bias based on earlier analyses in the same population 13, 14 . Every case (or control) that met the inclusion criteria and that could be matched to a control (case) was included in the analysis. COVID-19 vaccination status was ascertained at the time of the PCR test. Vaccine effectiveness was also estimated against any severe, critical, or fatal COVID-19 infection due to Omicron, using the same methodology. Classification of COVID-19 case All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101/2022.03.13.22272308 doi: medRxiv preprint severity (acute-care hospitalizations) 9 , criticality (intensive-care-unit hospitalizations) 9 , and fatality 10 followed World Health Organization (WHO) guidelines, and assessments were made by trained medical personnel using individual chart reviews (detailed description below). Each person who had a PCR-positive test result and COVID-19 hospital admission was subject to an infection severity assessment every three days until discharge or death, regardless of the hospital stay length or the time between the PCR-positive test and the final disease outcome. Individuals who progressed to severe 9 , critical 9 , or fatal 10 COVID-19 between the PCR-positive test result and the end of the study were classified based on their worst outcome, starting with death, followed by critical disease, and then severe disease. WHO defines severe COVID-19 as a SARS-CoV-2 infected individual with "oxygen saturation of <90% on room air, and/or respiratory rate of >30 breaths/minute in adults and children >5 years old (or ≥60 breaths/minute in children <2 months old or ≥50 breaths/minute in children 2-11 months old or ≥40 breaths/minute in children 1-5 years old), and/or signs of severe respiratory distress (accessory muscle use and inability to complete full sentences, and, in children, very severe chest wall indrawing, grunting, central cyanosis, or presence of any other general danger signs)" 9 . Detailed criteria are in the WHO technical report 9 . Critical COVID-19 is defined as a SARS-CoV-2 infected individual with "acute respiratory distress syndrome, sepsis, septic shock, or other conditions that would normally require the provision of life sustaining therapies such as mechanical ventilation (invasive or non-invasive) or vasopressor therapy" 9 . Detailed criteria are in the WHO technical report 9 . COVID-19 death is defined as "a death resulting from a clinically compatible illness, in a probable or confirmed COVID-19 case, unless there is a clear alternative cause of death that All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101/2022.03.13.22272308 doi: medRxiv preprint cannot be related to COVID-19 disease (e.g., trauma). There should be no period of complete recovery from COVID-19 between illness and death. A death due to COVID-19 may not be attributed to another disease (e.g., cancer) and should be counted independently of preexisting conditions that are suspected of triggering a severe course of COVID-19". Detailed criteria are in the WHO technical report 10 . Nasopharyngeal and/or oropharyngeal swabs were collected for PCR testing and placed in Universal Transport Medium (UTM). Aliquots of UTM were: 1) extracted on KingFisher Flex All PCR testing was conducted at the Hamad Medical Corporation Central Laboratory or at the Sidra Medicine Laboratory, following standardized protocols. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101/2022.03.13.22272308 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101/2022.03.13.22272308 doi: medRxiv preprint sequencing, and the remaining 4 failed sequencing). All the variant RT-qPCR genotyping was conducted at the Sidra Medicine Laboratory following standardized protocols. The large Omicron-wave exponential-growth phase in Qatar started on December 19, 2021 and peaked in mid-January, 2022 2-5 . The study duration coincided with the intense Omicron wave where Delta incidence was limited. Accordingly, any PCR-positive test during the study duration, between December 23, 2021 and February 28, 2022, was assumed to be an Omicron infection. Of note that the study duration started on December 23, 2021, and not on December 19, 2021, to minimize the occurrence of residual Delta incidence during the first few days of the Study samples were described using frequency distributions and measures of central tendency. Groups were compared using standardized mean differences (SMDs), defined as the difference in the mean of a covariate between groups, divided by the pooled standard deviation. SMD <0.1 indicated adequate matching 47 . The odds ratio (and 95% confidence interval (CI)), comparing odds of vaccination among cases to that among controls, was estimated using conditional logistic regression factoring the matching in the study design. This analytical approach was implemented to reduce potential bias due to variation in epidemic phase 11, 48 , gradual vaccination roll-out 11, 48 , and other confounders 15, [17] [18] [19] 49, 50 . CIs did not factor multiplicity and should not be used to infer All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101/2022.03.13.22272308 doi: medRxiv preprint definitive differences between study groups. Interactions were not examined. Vaccine effectiveness at different time frames and its associated 95% CI were then estimated using 11,12 : odds ratio of vaccination among cases versus controls Vaccine effectiveness 1 =− Since we used a test-negative study design, some persons were tested, PCR-positive or PCRnegative, after one vaccine dose, but before the next vaccine dose. This allowed us to estimate effectiveness after each dose. In each time-since-vaccination stratum, for first, second, and third doses, we analyzed only those vaccinated in this specific time-since-vaccination stratum and those unvaccinated (our reference group). Accordingly, the sample size for cases (and controls) varied in the different time-since-vaccination analyses. Effectiveness was estimated by one or more months in which one month was defined as 30 days, or by one or more weeks where one week was defined as 7 days. Sensitivity analyses were conducted to assess the impact on effectiveness estimates of adjusting for documented prior infection and healthcare worker status in conditional logistic regression. With the majority of those unvaccinated being children or young persons, and therefore not necessarily representative of total population demographics, additional analyses were conducted to assess the impact of excluding children <12 years of age and individuals <20 years of age on effectiveness estimates. Statistical analyses were conducted in STATA/SE version 17.0 51 . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101/2022.03.13.22272308 doi: medRxiv preprint The dataset of this study is a property of the Qatar Ministry of Public Health that was provided to the researchers through a restricted-access agreement that prevents sharing the dataset with a third party or publicly for preservation of confidentiality of patient data. Access to this dataset is at the discretion of the Qatar Ministry of Public Health. Access to the dataset can be considered through a direct application for data access to Her Excellency the Minister of Public Health (https://www.moph.gov.qa/english/Pages/default.aspx). Aggregate data are available within the manuscript and its supplementary information. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Abbreviations: CI, confidence interval; PCR, polymerase chain reaction. * A symptomatic infection was defined as a PCR-positive nasopharyngeal swab conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection. † In each analysis for a specific time-since-vaccination stratum, we included only those vaccinated in this specific time-since-vaccination stratum and those unvaccinated. Only matched pairs of PCR-positive and PCR-negative persons, in which both members of the pair were either unvaccinated or fell within each timesince-vaccination stratum have been included in the corresponding vaccine effectiveness estimate. Thus, the number of cases (and controls) varied across time-sincevaccination analyses. ‡ Vaccine effectiveness was estimated using the test-negative, case-control study design 1,2 . § Cases and controls were matched one-to-two by sex, 10-year age group, nationality, and calendar week of PCR test. ¶ Cases and controls were matched one-to-one by sex, 10-year age group, nationality, and calendar week of PCR test. ** Cases and controls were matched two-to-one by sex, 10-year age group, nationality, and calendar week of PCR test. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Abbreviations: CI, confidence interval; PCR, polymerase chain reaction. * A symptomatic infection was defined as a PCR-positive nasopharyngeal swab conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection. † In each analysis for a specific time-since-vaccination stratum, we included only those vaccinated in this specific time-since-vaccination stratum and those unvaccinated. Only matched pairs of PCR-positive and PCR-negative persons, in which both members of the pair were either unvaccinated or fell within each timesince-vaccination stratum have been included in the corresponding vaccine effectiveness estimate. Thus, the number of cases (and controls) varied across time-sincevaccination analyses. ‡ Vaccine effectiveness was estimated using the test-negative, case-control study design 1,2 . § Cases and controls were matched one-to-two by sex, 10-year age group, nationality, and calendar week of PCR test. ¶ Cases and controls were matched one-to-one by sex, 10-year age group, nationality, and calendar week of PCR test. ** Cases and controls were matched two-to-one by sex, 10-year age group, nationality, and calendar week of PCR test. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Summarise key results with reference to study objectives Discussion, paragraphs 1 & 2 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101/2022.03.13.22272308 doi: medRxiv preprint World Health Organization. Tracking SARS-CoV-2 variants National Project of Surveillance for Variants of Concern and Viral Genome Sequencing. Qatar viral genome sequencing data. Data on randomly collected samples Protection against the Omicron Variant from Previous SARS-CoV-2 Infection Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage. medRxiv Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar BA.1) and Sub-Variants (BA.1, BA.2 and BA.3) of SARS-CoV-2 Spike Infectivity and Pathogenicity: A Comparative Sequence and Structural-based Computational Assessment. bioRxiv Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine World Health Organization. COVID-19 clinical management: living guidance International guidelines for certification and classification (coding) of COVID-19 as cause of death The test-negative design for estimating influenza vaccine effectiveness Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar National Study Group for Covid Vaccination. Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19 SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals The test-negative design for estimating influenza vaccine effectiveness Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls Abbreviations: CI, confidence interval; PCR, polymerase chain reaction. * A symptomatic infection was defined as a PCR-positive nasopharyngeal swab conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection. † In each analysis for a specific time-since-vaccination stratum, we included only those vaccinated in this specific time-since-vaccination stratum and those unvaccinated. Only matched pairs of PCR-positive and PCR-negative persons, in which both members of the pair were either unvaccinated or fell within each timesince-vaccination stratum have been included in the corresponding vaccine effectiveness estimate. Thus, the number of cases (and controls) varied across time-sincevaccination analyses. ‡ Vaccine effectiveness was estimated using the test-negative, case-control study design 1,2 . § Cases and controls were matched one-to-two by sex, 10-year age group, nationality, and calendar week of PCR test. Abbreviations: CI, confidence interval; PCR, polymerase chain reaction. * A symptomatic infection was defined as a PCR-positive nasopharyngeal swab conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection. † In each analysis for a specific time-since-vaccination stratum, we included only those vaccinated in this specific time-since-vaccination stratum and those unvaccinated. Only matched pairs of PCR-positive and PCR-negative persons, in which both members of the pair were either unvaccinated or fell within each timesince-vaccination stratum have been included in the corresponding vaccine effectiveness estimate. Thus, the number of cases (and controls) varied across time-sincevaccination analyses. ‡ Vaccine effectiveness was estimated using the test-negative, case-control study design 1,2 . § Cases and controls were matched one-to-two by sex, 10-year age group, nationality, and calendar week of PCR test. ¶ Cases and controls were matched one-to-one by sex, 10-year age group, nationality, and calendar week of PCR test. ** Cases and controls were matched two-to-one by sex, 10-year age group, nationality, and calendar week of PCR test. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Abbreviations: CI, confidence interval; PCR, polymerase chain reaction. * A symptomatic infection was defined as a PCR-positive nasopharyngeal swab conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection. † In each analysis for a specific time-since-vaccination stratum, we included only those vaccinated in this specific time-since-vaccination stratum and those unvaccinated. Only matched pairs of PCR-positive and PCR-negative persons, in which both members of the pair were either unvaccinated or fell within each timesince-vaccination stratum have been included in the corresponding vaccine effectiveness estimate. Thus, the number of cases (and controls) varied across time-sincevaccination analyses. ‡ Vaccine effectiveness was estimated using the test-negative, case-control study design 1,2 . § Cases and controls were matched one-to-two by sex, 10-year age group, nationality, and calendar week of PCR test. ¶ Cases and controls were matched one-to-one by sex, 10-year age group, nationality, and calendar week of PCR test. ** Cases and controls were matched two-to-one by sex, 10-year age group, nationality, and calendar week of PCR test. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Abbreviations: CI, confidence interval; PCR, polymerase chain reaction. * A symptomatic infection was defined as a PCR-positive nasopharyngeal swab conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection. † In each analysis for a specific time-since-vaccination stratum, we included only those vaccinated in this specific time-since-vaccination stratum and those unvaccinated. Only matched pairs of PCR-positive and PCR-negative persons, in which both members of the pair were either unvaccinated or fell within each timesince-vaccination stratum have been included in the corresponding vaccine effectiveness estimate. Thus, the number of cases (and controls) varied across time-sincevaccination analyses. ‡ Vaccine effectiveness was estimated using the test-negative, case-control study design 1,2 . § Cases and controls were matched one-to-two by sex, 10-year age group, nationality, and calendar week of PCR test.